CAPELLA

Gilead Sciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
星期二, 十一月 7, 2023
Biotechnology, Pharmaceutical, AIDS, Oncology, General Health, Health, Infectious Diseases, Hospitals, BIRCH, Food, Pembrolizumab, B-cell lymphoma, Impact of the COVID-19 pandemic on hospitals, EPS, COVID-19, Tax rate, ETR, CAPELLA, Cohort study, Infection, Acute lymphoblastic leukemia, American Association for the Study of Liver Diseases, SARS-CoV-2, Earnings per share, HIV, GAAP, HCV, Safety, Patient, Food and Drug Administration, European Commission, Conference, Obeldesivir, Research, Growth, European, Lung cancer, Total, HDV, PD-L1, Research and development, Incidence, Hepatology, Axicabtagene ciloleucel, Omicron, Liver, Lung, Risk, Science, FTC, Table, Liver disease, HBV, Pharmaceutical industry, Video game, Fine chemical, Security (finance), Virology, Sacituzumab govitecan, Remdesivir

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
  • During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
  • During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock.
  • Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

Retrieved on: 
星期五, 十月 20, 2023
Science, Biotechnology, Research, Pharmaceutical, AIDS, Health, Hospitals, Clinical Trials, OBR, EACS, HIV/AIDS, MD, HIV, MDR, Conference, Doctor of Philosophy, Gilead Sciences, European, HIV-1, XVII International AIDS Conference, 2008, CAPELLA, Safety, Pharmaceutical industry, Lenacapavir

Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history.
  • The data were presented at the 19th European AIDS Conference ( EACS 2023 ) in Warsaw, Poland, from October 18-21.
  • “The bar is rightly now set high for the efficacy and safety of HIV treatment across a diverse range of people living with the virus.
  • Respondents reported that Sunlenca has strong potential to improve clinical outcomes and health-related quality of life for heavily treatment-experienced adults.

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

Retrieved on: 
星期一, 十月 16, 2023
Health, Hospitals, Research, Pharmaceutical, Science, Biotechnology, Partnership, PWH, Lenacapavir, XVII International AIDS Conference, 2008, Doctor of Philosophy, HIV Prevention Trials Network, Faculty, Drug development, Anxiety, Abstract, Drug resistance, European, EACS, Success, MD, Elton John AIDS Foundation, Risk, Chicano Art: Resistance and Affirmation, HIV-1, Death, Safety, HIV, EECA, CAPELLA, ART, DAI, Patient, CEST, Mental health, Education, Insomnia, Person, Mental, RSP, Tablet, Gilead Sciences, AIDS, Depression, History, Boxed warning, Elton, Conference, Monogram, Pharmaceutical industry, Medical device, Vaccine, Empowerment, Bictegravir/emtricitabine/tenofovir alafenamide

As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.

Key Points: 
  • As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.
  • Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance profile.
  • The mental health outcomes reported by participants in BICSTaR over a two-year period will also be presented at EACS 2023.
  • Mental health impairments can further increase the risk of negative health outcomes at every stage of the HIV care continuum.

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023

Retrieved on: 
星期二, 十月 3, 2023
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, XBF, Abstract, Gilead Sciences, Omicron, Senior, HIV, Obeldesivir, Virology, SARS-CoV-2, Safety, Pre-exposure prophylaxis, Lenacapavir, HIV capsid inhibition, Tablet, Drug resistance, MD, Patient, Boxed warning, Liver, CAPELLA, Pharmaceutical industry, Bictegravir/emtricitabine/tenofovir alafenamide, Remdesivir

These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19.

Key Points: 
  • These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19.
  • Gilead will be presenting 16 abstracts, including real-world evidence, as the company continues to pursue the next wave of scientific discovery in virology.
  • “At IDWeek 2023, we look forward to sharing our latest data with the broader community and discussing potential implications for the treatment of COVID-19 among some of the most vulnerable populations.
  • At IDWeek 2023, Gilead will present data that reinforces the ongoing role Veklury® (remdesivir) plays as the antiviral standard of care for the treatment of hospitalized patients with COVID-19.

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV

Retrieved on: 
星期二, 七月 25, 2023
AIDS, Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, HIV, Week, Hospital, Aes, OBR, Lenacapavir, Saint Louis University School of Medicine, Plasma, United Arab Emirates, MD, OB, Patient, European, United Kingdom, Infection, Safety, Pharmaceutical industry, Vaccine, Medical device, CAPELLA

In CALIBRATE, in a missing equals excluded analysis, 100% of all participants at Week 10, 20, and 30 were virologically suppressed (77/77; 58/58; 5/5, respectively).

Key Points: 
  • In CALIBRATE, in a missing equals excluded analysis, 100% of all participants at Week 10, 20, and 30 were virologically suppressed (77/77; 58/58; 5/5, respectively).
  • One CAPELLA participant who missed two non-consecutive oral lenacapavir doses did not maintain virologic suppression during OB.
  • Overall, OB demonstrated a consistent safety and tolerability profile, with treatment-emergent adverse events (AEs) similar to subcutaneous lenacapavir.
  • The use of twice-yearly lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.

Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023

Retrieved on: 
星期三, 七月 19, 2023
AIDS, Health, Infectious Diseases, Hospitals, Pharmaceutical, Biotechnology, Science, Emtricitabine, Maintenance, Gilead Sciences, Elton, Bictegravir/emtricitabine/tenofovir alafenamide, International, Public affairs, Senior, HIV, Health equity, AEST, Woman, Lenacapavir, Research, Doctor of Philosophy, Tablet, Elton John AIDS Foundation, DTG, HIV/AIDS denialism, MD, The Fire Within, IAS, Crisis communication, Conference, CAPELLA, Pharmaceutical industry

As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.

Key Points: 
  • As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.
  • Gilead is committed to continuous scientific discovery to meet the evolving needs of people affected by HIV.
  • At IAS 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.
  • Gilead scientists will also contribute to three IAS-hosted satellite sessions to further advance scientific dialogue on key issues including:

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV

Retrieved on: 
星期四, 十二月 22, 2022
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Hospitals, Science, Clinical Trials, Plasma protein binding, MDR, Science, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV, Weill Cornell Medicine, HIV-1, Multimedia, Pre-exposure prophylaxis, ARV, Gilead Sciences, Subtypes of HIV, News, Lenacapavir, NewYork-Presbyterian Queens, Viral load, Infection, HTE, Patient, Medicine, Physician, CAPELLA, Safety, FDA, Pharmaceutical industry, MD

Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen.

Key Points: 
  • Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen.
  • “The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced people with multi-drug resistant HIV.
  • Despite the significant advances in ARV therapy, there remain numerous critical and pressing unmet needs for people living with HIV.
  • This type of complexity further increases the chance of treatment failure, underscoring the need for new treatment options that are active against resistant variants of the virus with a novel mechanism of action.

Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022

Retrieved on: 
星期二, 十月 18, 2022
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, European Medicines Agency, Union, Kidney, Infection, PRT, Assessment of kidney function, HIV/AIDS, Dofetilide, Person, Fanconi syndrome, Emtricitabine, TAF, Patient, Rifampicin, HIV, International Congress on Tuberculosis, European Market Infrastructure Regulation, RNA, CAPELLA, Research, Gilead Sciences, HIV-1, History, AIDS, TDF, Hepatitis B, Sex, Pharmacotherapy, Creatinine, Drug interaction, Drug, Disulfiram-like drug, MD, Doctor of Philosophy, Science, Contraindication, Boxed warning, Safety, FTC, 2021 Essex County Council election, Product, HBV, Degenerative disease, Week, Nasdaq, Lenacapavir, Kidney failure, Medication package insert, Tablet, Postmarketing surveillance, Pharmaceutical industry, Vaccine, Bictegravir/emtricitabine/tenofovir alafenamide, EU

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.
  • The data presented at HIV Glasgow reflect the latest progress in our research and development programs and underscore Gileads commitment to driving transformational innovation in HIV research.
  • Biktarvy, Sunlenca, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

Retrieved on: 
星期一, 八月 22, 2022
AIDS, Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Saint Louis encephalitis, CAPELLA, Lenacapavir, Tablet, AIDS, Infection, Science, MAA, Nasdaq, Physician, Royal commission, HIV, HIV/AIDS, MD, Â, Population, EC, Hospital, Risk, European Commission, Viral load, Patient, Pharmaceutical industry

After more than three decades of driving advancements in HIV treatment and prevention, Gilead scientists have now delivered an innovative new option for long-acting care, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences.

Key Points: 
  • After more than three decades of driving advancements in HIV treatment and prevention, Gilead scientists have now delivered an innovative new option for long-acting care, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences.
  • Following todays approval, it will now be the only twice-yearly treatment for people who struggle with multi-drug resistant HIV.
  • Sunlenca, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic

Retrieved on: 
星期四, 七月 21, 2022
Science, Biotechnology, Research, Pharmaceutical, AIDS, Health, Hospitals, Clinical Trials, PRT, Emtricitabine, Creatinine, Lenacapavir, Kidney failure, TAF, Postmarketing surveillance, Doctor of Philosophy, 2021 Essex County Council election, Tablet, International AIDS Society, Research, HIV-1, Biomarker, History, Partnership, Boxed warning, Solution, DTG, Vesatolimod, Drug interaction, Randomized controlled trial, Drug, Degenerative disease, Nasdaq, FTC, TDF, Contraindication, Safety, COVID-19, Conference, Kidney, Hepatitis B, Dofetilide, AIDS, Senior, MD, CAPELLA, Gilead Sciences, COMPASS, Pharmacokinetics, Patient, Science, Assessment of kidney function, Fanconi syndrome, International, Subtypes of HIV, Rifampicin, HIV, ART, Public affairs, HBV, Pharmaceutical industry, Dietary supplement, Vaccine, Bictegravir/emtricitabine/tenofovir alafenamide

The convergence of the COVID-19 pandemic and HIV epidemic has further highlighted how inequities result in adverse health outcomes.

Key Points: 
  • The convergence of the COVID-19 pandemic and HIV epidemic has further highlighted how inequities result in adverse health outcomes.
  • At AIDS 2022, Gilead will convene a diverse, global panel Working Together to End the Epidemic: Guided by the Voices on the Ground to discuss community perspectives and Gileads ongoing efforts to change the future of the HIV epidemic through catalytic collaboration.
  • Gilead is driving scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere.
  • During AIDS 2022, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the companys continued pursuit of an HIV cure.